EP1001967A1 - Behandlungsmethode eines lignocellulosischen materials oder eines expandierten minerals zur formung eines fertigproduktes - Google Patents
Behandlungsmethode eines lignocellulosischen materials oder eines expandierten minerals zur formung eines fertigproduktesInfo
- Publication number
- EP1001967A1 EP1001967A1 EP98935519A EP98935519A EP1001967A1 EP 1001967 A1 EP1001967 A1 EP 1001967A1 EP 98935519 A EP98935519 A EP 98935519A EP 98935519 A EP98935519 A EP 98935519A EP 1001967 A1 EP1001967 A1 EP 1001967A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- irf
- sequence
- hsv
- reactivation
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 77
- 238000012216 screening Methods 0.000 title claims abstract description 14
- 230000007419 viral reactivation Effects 0.000 title claims description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 143
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 134
- 229920001184 polypeptide Polymers 0.000 claims description 132
- 102000040430 polynucleotide Human genes 0.000 claims description 85
- 108091033319 polynucleotide Proteins 0.000 claims description 85
- 239000002157 polynucleotide Substances 0.000 claims description 85
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 claims description 76
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 claims description 76
- 230000027455 binding Effects 0.000 claims description 45
- 101000999377 Homo sapiens Interferon-related developmental regulator 1 Proteins 0.000 claims description 40
- 102100036527 Interferon-related developmental regulator 1 Human genes 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 27
- 108010050904 Interferons Proteins 0.000 claims description 24
- 102000014150 Interferons Human genes 0.000 claims description 22
- 241000700605 Viruses Species 0.000 claims description 22
- 230000001105 regulatory effect Effects 0.000 claims description 22
- 230000037361 pathway Effects 0.000 claims description 21
- 108091035707 Consensus sequence Proteins 0.000 claims description 15
- 241001529453 unidentified herpesvirus Species 0.000 claims description 15
- 208000036142 Viral infection Diseases 0.000 claims description 13
- 230000002068 genetic effect Effects 0.000 claims description 13
- 230000009385 viral infection Effects 0.000 claims description 13
- 229940079322 interferon Drugs 0.000 claims description 12
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 10
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 229940037201 oris Drugs 0.000 claims description 8
- 230000003042 antagnostic effect Effects 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 6
- 230000009870 specific binding Effects 0.000 claims 4
- 230000001413 cellular effect Effects 0.000 abstract description 33
- 208000015181 infectious disease Diseases 0.000 abstract description 16
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract description 14
- 230000000840 anti-viral effect Effects 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 208000029433 Herpesviridae infectious disease Diseases 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 description 102
- 210000004027 cell Anatomy 0.000 description 82
- 108020004414 DNA Proteins 0.000 description 57
- 210000000427 trigeminal ganglion Anatomy 0.000 description 57
- 102000004169 proteins and genes Human genes 0.000 description 52
- 241000700584 Simplexvirus Species 0.000 description 50
- 230000014509 gene expression Effects 0.000 description 49
- 230000007420 reactivation Effects 0.000 description 44
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
- 230000006698 induction Effects 0.000 description 38
- 239000000047 product Substances 0.000 description 38
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 37
- 239000013598 vector Substances 0.000 description 33
- 125000003729 nucleotide group Chemical group 0.000 description 30
- 239000002773 nucleotide Substances 0.000 description 29
- 108091026890 Coding region Proteins 0.000 description 28
- 108020004635 Complementary DNA Proteins 0.000 description 26
- 239000012634 fragment Substances 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 210000002569 neuron Anatomy 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 238000010804 cDNA synthesis Methods 0.000 description 20
- 239000002299 complementary DNA Substances 0.000 description 20
- 230000003612 virological effect Effects 0.000 description 19
- 241001529936 Murinae Species 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 102100029838 Interferon regulatory factor 2 Human genes 0.000 description 15
- 108090000908 Interferon regulatory factor 2 Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000010076 replication Effects 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 14
- 108090000467 Interferon-beta Proteins 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 102100026720 Interferon beta Human genes 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229940047124 interferons Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000035882 stress Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 206010020843 Hyperthermia Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 8
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 210000000609 ganglia Anatomy 0.000 description 8
- 230000036031 hyperthermia Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000001493 Cyclophilins Human genes 0.000 description 7
- 108010068682 Cyclophilins Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108091029865 Exogenous DNA Proteins 0.000 description 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000012300 Sequence Analysis Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000006382 Ribonucleases Human genes 0.000 description 6
- 108010083644 Ribonucleases Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 230000006648 viral gene expression Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 4
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 230000001323 posttranslational effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108091006106 transcriptional activators Proteins 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 3
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 3
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101000713899 Rattus norvegicus Activated RNA polymerase II transcriptional coactivator p15 Proteins 0.000 description 3
- 101001072083 Rattus norvegicus Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000006225 natural substrate Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GYHXNGRPRPFNOF-UHFFFAOYSA-N 2-amino-5-[[1-(carboxymethylamino)-1-oxo-3-sulfanylbutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CNC(=O)C(C(S)C)NC(=O)CCC(N)C(O)=O GYHXNGRPRPFNOF-UHFFFAOYSA-N 0.000 description 2
- 101710111216 Activated RNA polymerase II transcriptional coactivator p15 Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 2
- 102000034575 Glutamate transporters Human genes 0.000 description 2
- 108091006151 Glutamate transporters Proteins 0.000 description 2
- 241000700589 Herpes simplex virus (type 1 / strain 17) Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- -1 IFNαβR Proteins 0.000 description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 101710180646 Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 101150102071 TRX1 gene Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102000004408 Transcription factor TFIIB Human genes 0.000 description 2
- 108090000941 Transcription factor TFIIB Proteins 0.000 description 2
- 101150090946 UL38 gene Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108010007981 gamma-glutamyl-thiothreonyl-glycine Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 210000000413 sensory ganglia Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- SUHQNCLNRUAGOO-KQCZLNONSA-N (4s,5r,6r,7s,8r)-4,6,7,8,9-pentahydroxy-5-[(2-hydroxyacetyl)amino]-2-oxononanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](NC(=O)CO)[C@@H](O)CC(=O)C(O)=O SUHQNCLNRUAGOO-KQCZLNONSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 101000818123 Acholeplasma phage L2 Uncharacterized 17.2 kDa protein Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101150000167 BMRF2 gene Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101000786247 Bacillus subtilis (strain 168) Uncharacterized protein YqaT Proteins 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 238000012287 DNA Binding Assay Methods 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 101710135281 DNA polymerase III PolC-type Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000210651 Enterobacteria phage 1 Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000714475 Fujinami sarcoma virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101001052021 Haemophilus phage HP1 (strain HP1c1) Probable tail fiber protein Proteins 0.000 description 1
- 101000818121 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 18.2 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101150102264 IE gene Proteins 0.000 description 1
- 101150103227 IFN gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 101000790842 Klebsiella pneumoniae Uncharacterized 65.4 kDa protein in cps region Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 101000748779 Marchantia polymorpha Uncharacterized 6.4 kDa protein in atpA-psbA intergenic region Proteins 0.000 description 1
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101000800132 Mus musculus Thyroglobulin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 101000781204 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 36.6 kDa protein Proteins 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000015864 Protobothrops flavoviridis Species 0.000 description 1
- 101000953580 Pseudomonas phage Pf1 8.6 kDa protein Proteins 0.000 description 1
- 101000953577 Pseudomonas phage Pf3 7.9 kDa protein Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 101001044455 Rattus norvegicus Interferon gamma Proteins 0.000 description 1
- 101000595041 Rattus norvegicus Podocalyxin Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101000708364 Streptomyces griseus Uncharacterized 31.2 kDa protein in rplA-rplJ intergenic region Proteins 0.000 description 1
- 101000953979 Streptomyces lividans Uncharacterized 6.6 kDa protein Proteins 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 101000626900 Trieres chinensis Uncharacterized 5.5 kDa protein in ccsA-rps6 intergenic region Proteins 0.000 description 1
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940052810 complex b Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000002990 hypoglossal effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 108010051621 interferon regulatory factor-8 Proteins 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000026206 response to starvation Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000009844 retrograde axon cargo transport Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000007733 viral latency Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to newly identified attributes of cellular and viral polynucleotides and polypeptides, the uses of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides.
- This invention also relates to inhibiting the biosynthesis, action or interaction of such polynucleotides and/or polypeptides and to the use of such inhibitors in therapy, particularly therapy for viral reactivation, especially Herpesvirus reactivation, as well as for prophylaxis.
- HSV latent Herpes simplex virus
- the virus can undergo sporadic reactivation to produce recurrent mucocutaneous lesions at peripheral sites innervated by the infected ganglia (reviewed in Fraser et al., 1991, Roizman, 1991, Stevens, 1989).
- Reactivation stimuli range from direct mechanical or pharmacological insults to the neuron and surrounding tissue to systemic changes in immune modulators and neurotransmitters (Fraser et al., 1991, Fraser & Valyi-Nagy, 1993, Hill, 1985). The earliest molecular events in neuronal cells that trigger reactivation of HSV remain unclear.
- the present invention provides cellular factors with a putative role in the reactivation process of Herpesviruses, particularly HSV-1, HSV-2, varicella zoster virus (herein “VZV”), Epstein Barr virus (herein “EBV”) and human cytomegalovirus (herein “HCMV”).
- This invention was made, in part, using differential display RT-PCR (DDRT- PCR), which allows the visualization and subsequent isolation of cDNAs corresponding to mRNAs displaying altered expression in different cell populations (Liang et al, 1995, Liang & Pardee, 1992). Using this method, levels of gene expression in TG populations derived from various time points following explantation were compared.
- any factors modulated during the first 4 hours, the period in which viral gene expression is first detected are believed to be important in the initial stimulation of latent viral genomes.
- DDRT-PCR has also been used to identify cellular genes modulated by SV40 and EBV transformation (Sompayrac et al, 1996, Yan et al, 1996). However, it is a novel approach to study viral reactivation.
- This invention demonstrates the isolation of forty eight differentially-displayed cDNAs representing transcripts whose levels were altered within the first 4 hours following explantation of latently infected TG.
- Five cDNAs were identical to murine TIS7, whose sequence has been shown to be related to interferons (IFNs) (Skup et al, 1982, Tirone & Shooter, 1989, Varnum et al, 1989). Rapid induction of IFNs ⁇ and ⁇ in neuronal cells of TG explants was also detected.
- IFN-1 Interferon Regulatory Factor -1
- TNF- ⁇ tumor necrosis factor -a
- Figure 1 shows PCR differential-display of cDNA derived from latently-infected mouse TG following explantation. Autoradiograph of radiolabeled DDRT-PCR products. Arrows denote PCR products representing (Left Panel) band #64 amplified with 3' primer #2 and 5' primer #7, (Right Panel) band #56 amplified with 3' primer #2 and 5' primer #3.
- Figure 2 shows sequences of DDRT-PCR products. cDNAs isolated from differential-display gels were reamplified using primers that included the T7 promoter sequence, and PCR products sequenced. Sequences were analyzed by BLAST searches.
- Figure 3 shows confirmation of differential display.
- RNA was prepared from uninfected TG explants at 0, 1, 2, and 4 h p.e.
- Complementary DNA from differentially displayed band #56 was reamplified by PCR using 3' primers that included the T7 promoter. PCR products were used as templates to prepare riboprobes labeled with 32" P- UTP, and added to each RNA sample. Following hybridization at 37°C and RNase digestion, samples were separated by PAGE.
- P The input probe (P) and protected fragments were visualized using phosphorimager screens.
- Panel B The intensity of each protected fragment was quantitated using Imagequant software. Fold induction was expressed as the ratio between each band to the 0 time point.
- RT-PCR was used to detect (Panel A) IFN- ⁇ , (Panel B) IRF-1, (Panel C) IFN ⁇ R, (Panel D) IRF-2, and each was compared to the level of cyclophilin mRNA.
- Duplicate samples of TG explant RNA from 0, 1, 2, and 4 h post- explantation were analysed. Products were separated by agarose gel electrophoresis, followed by fluorimager scanning and analysis using Imagequant software. The relative amount of cDNA is expressed in these graphs in arbitrary units representing the ratio between the intensity of the PCR-product band to the intensity of cyclophilin. The ratio at the 0 time point is designated as 1.
- L indicates latent.
- Figure 5 shows immunostaining of interferon protein in TG following.
- Latently- infected or uninfected BALB/c mice were sacrificed, TG were excised, and incubated in culture media for 0-24 h p.e.
- Paraffin-embedded sections were processed as described in Methods and reacted with rabbit polyclonal antisera against IFN ⁇ and ⁇ .
- E 0 h p.e. of uninfected TG,
- F 4 h p.e. of uninfected TG.
- FIG. 6 shows RT-PCR detection of TNF- ⁇ , cyclophilin, and ⁇ -actin transcripts in murine TG cultured for varying times post explantation.
- RNA from latently-infected TG explants was prepared and analyzed by RT-PCR for (Panel A) TNF- ⁇ , and (Panel B) ⁇ - actin, and cyclophilin, as described in Materials and Methods. Products were visualized by ethidium bromide staining as shown in the inserts.
- the graphs represent the ratio between the PCR product band and the cyclophilin band. The ratio at the time of explantation (0) was determined as 1. Experiments were done in duplicate in four separate experiments.
- Figure 7 shows the locations and sequences of IRF-1 consensus binding sites in the genome of HSV- 1 , with reference to the nucleotide numbering system of GENEMBL entry HE1CG.
- FIG 8 shows that IRF-1 binds specifically to HSV-1 LAT DNA consensus sequence.
- IRF-1 binds specifically to HSV-1 LAT DNA consensus sequence.
- In vitro translated human IRF-1 was incubated with 32-p_ ⁇ a b e ] e( j LAT probe in the presence or absence of antisera specific for IRF- 1 or IRF-2.
- Samples were analyzed by electromobility shift assay (EMS A). Probe alone was used as control.
- Figure 9 shows that IRF-2 binds specifically to LAT DNA. Competition experiments were carried out with mutant LAT oligonucleotides.
- FIG. 10 shows that TIS7 and IRF-1 are induced by hyperthermia measured by heat shock protein 70 (HSP70) induction.
- HSP70 heat shock protein 70
- This invention provides cellular proteins from murine trigeminal ganglia induced by the stress of injury in viral infection and/or reactivation.
- polynucleotides which bind such polypeptides, or which alter the biological activity of such polypeptides.
- the invention provides polynucleotides having the DNA sequences given herein.
- the invention also relates to novel oligonucleotides derived from the sequences given herein which can act as PCR primers in the process herein described to determine, for exaple, whether or not the genes identified herein in whole or in part are expressed in an infected tissue or individual. It is recognised that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.
- the proteins so identified are also useful as targets in screens designed to identify antiviral compounds.
- a polypeptide and/or polynucleotide of the invention for therapeutic or prophylactic purposes, for example, as an antiviral agent or a vaccine.
- polypeptides and/or polypeptide of the invention for therapeutic or prophylactic purposes.
- inhibitors or activators to such polypeptides and/or polynucleotides useful as antiviral agents.
- antibodies against such polypeptides and polypeptide-polynucleotide complexes are provided.
- Another aspect of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising the above polypeptide, polynucleotide, inhibitor or activator of the invention and a pharmaceutically acceptable carrier.
- the invention provides the use of an activator or inhibitor of the invention as an antiviral agent.
- the invention further relates to the manufacture of a medicament for such uses, particularly a medicament to treat HSV-1 and/or HSV-2 infection or reactivation.
- composition comprising IRF-1, particularly used as a screening target for the development of prophylactic and therapeutic compounds, such as compounds that interfere with HSV (herein "HSV” means HSV-1 and or HSV-2) or VZV reactivation.
- HSV HSV-1 and or HSV-2
- VZV reactivation a method for inhibiting the binding of IRF-1 to a polynucleotide, such as a DNA element (for example, ISRE's), particulary DNA comprising or near a viral origins of replication.
- a polynucleotide such as a DNA element (for example, ISRE's), particulary DNA comprising or near a viral origins of replication.
- a further aspect of the invention is a composition comprising an IRF- 1 : IRF-BP complex.
- reactivation means viral reactivation from latency
- compositions comprising IRF- 1 binding site consensus sequences in HSV oriL and oriS and HSV long terminal repeats.
- Vector(s) of the invention refers, among others, to a polypeptide comprising the amino acid sequence any or a combination of the factors involved in viral infection and/or reactivation disclosed herein, such as IRF-1, TIS7, IFN- ⁇ and IFN- ⁇ , or an allelic variant thereof; also included are polynucleotides encoding any of these polypeptides.
- Biological Activity of the Receptor refers to the metabolic or physiologic function of said Factors of the invention including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said Factors of the invention.
- Factor gene(s) refers to a polynucleotide comprising the nucleotide sequence encoding a Factor of the invention or allelic variants thereof and/or their complements.
- Antibodies as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library. "Isolated” means altered “by the hand of man” from the natural state. If an
- isolated composition or substance occurs in nature, it has been changed or removed from its original environment, or both.
- a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.
- Polynucleotide generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- Polynucleotides include, without limitation single- and double- stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
- polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- the term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
- Modified bases include, for example, tritylated bases and unusual bases such as inosine.
- polynucleotide embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.
- Polynucleotide also embraces relatively short polynucleotides, often referred to as oligonucleotides.
- Polypeptide refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.
- Polypeptide refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
- Polypeptides include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.
- Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
- Modifications include acetylation, acylation, ADP- ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
- Variant is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties.
- a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide.
- Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
- a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
- a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
- a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
- a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally.
- Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.
- Identity is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. “Identity” per se has an art-recognized meaning and can be calculated using published techniques.
- identity is well known to skilled artisans (Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48: 1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48: 1073. Methods to determine identity and similarity are codified in computer programs.
- Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al, Nucleic Acids Research (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. et al, J Molec Biol (1990) 215:403).
- a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1.
- a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
- These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
- a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence of is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid sequence.
- up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
- alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
- “Individual(s)” means a eukaryote, particularly a mammal, and especially a human, particularly one infected with a virus or believed to be infected by a virus.
- Plasmids are designated by a lower case p preceded and/or followed by capital letters and/or numbers.
- the starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures.
- equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.
- “Digestion” of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA.
- the various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan.
- For analytical purposes typically 1 ⁇ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 ⁇ l of buffer solution.
- For the purpose of isolating DNA fragments for plasmid construction typically 5 to 50 ⁇ g of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37 C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment.
- Size separation of the cleaved fragments is performed using 8 percent polyacrylamide gel described by Goeddel, D. et al, (1980) Nucleic Acids Res., 8:4057.
- Oligonucleotides refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated. "Ligation” refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T., et al, supra., p.
- ligation may be accomplished using known buffers and conditions with 10 units to T4 DNA ligase ("ligase”) per 0.5 ⁇ g of approximately equimolar amounts of the DNA fragments to be ligated.
- ligase DNA ligase
- a "replicon” is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.
- a “vector” is a replicon, such as a plasmid, phage, or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.
- a “double-stranded DNA molecule” refers to the polymeric form of deoxyribonucleotides (bases adenine, guanine, thymine, or cytosine) in a double-stranded helix, both relaxed and supercoiled. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms.
- this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes.
- sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having the sequence homologous to the mRNA).
- a DNA "coding sequence of” or a "nucleotide sequence encoding" a particular protein is a DNA sequence which is transcribed and translated into a polypeptide when placed under the control of appropriate regulatory sequences.
- a “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence.
- the promoter sequence is bound at the 3' terminus by a translation start codon (e.g., ATG) of a coding sequence and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
- a transcription initiation site (conveniently defined by mapping with nuclease SI), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
- Eukaryotic promoters will often, but not always, contain "TATA” boxes and “CAT” boxes.
- Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.
- DNA "control sequences” refers collectively to promoter sequences, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the expression (i.e., the transcription and translation) of a coding sequence in a host cell.
- a control sequence "directs the expression" of a coding sequence in a cell when RNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.
- a "host cell” is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous DNA sequence.
- a cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane.
- Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
- the exogenous DNA may be maintained on an episomal element, such as a plasmid.
- a stably transformed or transfected cell is one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cell containing the exogenous DNA.
- a “clone” is a population of cells derived from a single cell or common ancestor by mitosis.
- a “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.
- a "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature.
- DETAILED DESCRIPTION OF THE INVENTION Applicants have discovered that cellular interferon-related genes are induced in tissues in response to certain stimuli as described herein.
- the tissue studied is primarily nerve tissue (ganglia) where HSV and other Herpesviruses establish latent infections. These stimuli also induce reactivation of HSV and other Herpesviruses from latency into active replication.
- IRF-1 an important cellular regulatory protein
- HSV and other Herpesviruses replication through the identification of IRF-1 binding sites in the DNA sequence of HSV and other Herpesviruses DNA.
- IRF-1 and/or the IRF-1 regulatory pathway, are essential for reactivation of HSV and other Herpesviruses from latency, and that pharmacological interference with this pathway will interfere with HSV and other Herpesvirus reactivation resulting in arrest of clinical disease.
- the invention provides various targets for screening for therapeutic compounds using the methods described herein.
- targets include, for example, IRF-1.
- a compound interfering with HSV and other Herpesvirus reactivation by inhibiting the binding of IRF-1 to viral DNA elements (ISRE's) may be found using such screens and are useful in antiviral therapy, especially against HSV and other Herpesviruses.
- IRF-1 IRF-BP complex
- IRF-1 and IRF-BP can be used to screen for compounds interfering with HSV reactivation by, among other modes of action, freezing or mimicking the binding of IRF-1 to it's inhibitor factor IRF-BP.
- Such compounds are useful in antiviral therapy, especially against HSV.
- target include any element in the IRF-1 and interferon genetic regulatory pathway which subsequently impacts HSV reactivation from latency. These compounds are useful to screen for antiviral compounds. Such compounds are useful in antiviral therapy, especially against HSV.
- Yet another target are polynucleotides derived from or comrpising an IRF-1 binding site consensus sequences in HSV LAT/ICPO, oriL and oriS play a significant role in HSV replication. A preferred embodiment of this sequence is set forth in SEQ ID NO: 1. Such compounds are useful in antiviral therpy, especially against HSV.
- DDRT differential display RT-PCR
- IFN-related gene transcripts including IFN- ⁇ , and the interferon regulatory factor- 1 (IRF-1) were induced following explantation of murine trigeminal ganglia (Tal-Singer et al. 1998).
- IRF-1 interferon regulatory factor-1
- IRF-1 is a transcriptional activator and tumor supressor protein which regulates interferon genes transcription such as IL-1 beta (via Interleukin Converting Enzyme (ICE) pathways) (Tamura et al, 1996), and MHC-I expression (Drew et al, 1995, Hobart et al, 1997). It is activated by interferons and the STATl pathway (Pine et al, 1994). It binds to cellular proteins such as TFIIB, and NFKB (Drew et al, 1995, Wang et al, 1996). Its DNA binding and transcriptional activation functions are inhibited when it is bound to IRF-BP protein (Kondo, 1996). Its known functions involve the inflammatory response and regulation of the cell cycle via induction of p21 (Tanaka et al, 1996).
- ICE Interleukin Converting Enzyme
- Targets include any element in the IRF-1 and interferon genetic regulatory pathway which subsequently impacts HSV reactivation from latency. These compounds are useful to screen for antiviral compounds. Such compounds are useful in antiviral therapy, especially against HSV.
- Yet another target are polynucleotides derived from or comrpising an IRF-1 binding site consensus sequences in HSV LAT/ICPO, oriL and oriS which play a significant role in HSV replication.
- a preferred embodiment of this sequence is set forth in SEQ ID NO:l.
- Such compounds are useful in antiviral therpy, especially against HSV.
- murine trigeminal ganglia explants were analyzed by differential display RT-PCR (DDRT).
- IRF-1 is a transcriptional activator and tumor supressor protein which regulates interferon genes transcription such as IL- 1 beta (via Interleukin Converting Enzyme (ICE) pathways) (Tamura et al, 1996), and MHC-I expression (Drew et al, 1995, Hobart et al, 1997)]. It is activated by interferons and the STATl pathway (Pine et al, 1994). It binds to cellular proteins such as TFIIB, and NFkB (Drew et al, 1995, Wang et al, 1996). Its DNA binding and transcriptional activation functions are inhibited when it is bound to IRF-BP protein (Kondo, 1996). Its known functions involve the inflammatory response and regulation of the cell cycle via induction of p21 (Tanaka et al, 1996).
- ICE Interleukin Converting Enzyme
- IRF-1 is a member of a multigene family which recognizes the same promoter consensus sequence (herein referred to as "ISRE” or "ICS"). Sequence analysis using Findpatterns function of the GCG software (Genetics Computer Group, Madison, Wisconsin). HSV-1 complete genome sequence (Genbank locus HE1CG accession # X14112) was searched for the core consensus IRF-1 site in interferon promoters using the hexamer AAGTGA (Tanaka & Taniguchi, 1992). Sequence matches are listed in Table 1 by sequence location, and gene name. Ten identical matches were found in in HSV-1 strain 17+ sequence (see Figure 7).
- Binding Site HI is within regions previously identified as origin binding protein (OBP or UL9) Binding Site HI. Also, of great interest are previous observations that, in addition to binding OBP, Binding Site HI interacts with yet unknown cellular proteins (Dabrowski et al., 1991; Dabrowski et al, 1994). Taken together, these observations suggest that IRF-1 may bind to regulatory elements in the viral genome such as the origins of replication, and ICPO/LAT, and thereby upregulate viral replication or gene expression. Interestingly, functional ERF binding sites recently were identified in the herpesvirus Epstein-Barr virus (EBV) (Schaffer et al, 1997; Nonkwelo et al, 1997).
- EBV herpesvirus Epstein-Barr virus
- IRF-1 and IRF-2 bind directly to consensus sequence sites in the EBV Type I latency promoter of EBNA-1 (Qp), and IRF factors may play a primary role in transcriptional regulation of EBNA-1 in cell culture (Schaffer et al, 1997; Nonkwelo et al, 1997).
- IRF-1 consensus sequences include, for example, the following sequences in Table 1. Highly conserved nucleotides surrounding the core are bold and underlined.
- Epstein Barr Virus Ebv.Gb_Vi 1 AAGTGA
- Applicants have also used, for example, DDRT-PCR to identify genes differentially expressed following the stress caused by explantation of latently-infected murine TG.
- Mice were infected by the corneal route with HSV-1, and at 4 weeks post infection, mice were sacrificed and the TG were explanted.
- RNA was prepared from TG at various times following explantation, followed by DDRT-PCR.
- TIS7 is induced by the stress of explantation. Five differentially displayed bands were identified as overlapping regions of murine TIS7 (Lim et al, 1987, Varnum et al, 1989) ( Figure 2) and the results were confirmed by quantitative RPA and RT-PCR ( Figure 3).
- the TIS (TPA-inducible sequences) family members are early response genes (Walz et al, 1976) which are induced rapidly and transiently in Swiss 3T3 cells by the tumor promoter mitogen tetradecanoyl phorbol acetate (TPA) (Lim et al, 1987), or by serum (Herschman, 1991).
- TIS genes also have been identified in rat PC 12 cells, following induction with NGF, TPA, epidermal growth factor and depolarization (Kujubu et al, 1987). Moreover, TIS induction has been detected in primary astrocyte cultures following mitogen induction (Arenalder et al, 1989). Thus, a family of ⁇ S genes appear to constitute a common pathway or response to many cell stimulatory agents or physical stimuli.
- TIS7/PC4 genes The pattern of induction previously observed for TIS7/PC4 genes in these systems revealed an increase in the levels of RNA or protein between 2-4 hours post stimulus (Varnum et al, 1994), similar to our observation in the mouse explant model ( Figure 2).
- Applicants have shown that another TIS transcript, TIS28 or c-fos, was induced rapidly following explantation (Tal-Singer et al, 1997, Valyi-Nagy et al, 1991), and again, the kinetics match those previously observed following mitogen induction (Arenalder et al, 1989).
- rat PC4 highly related to murine TIS7
- c-fos are both induced by activation of the oncogenenic protein-tyrosine kinase v-fps, encoded in the retrovirus Fujinami sarcoma virus (Jahner & Hunter, 1991). It would be of interest to determine whether a similar kinase, either of viral or cellular origin, is activated in explanted ganglia or in other HSV reactivation systems.
- Interferon ⁇ is induced by the stress of explantation.
- TIS7 was originally identified as a gene induced in murine 3T3 cells following infection with Newcastle disease virus (Skup et al, 1982). Nucleotide sequence analysis revealed some conservation with human IFN- ⁇ and rat IFN- ⁇ (Tirone & Shooter, 1989). The present invention provides that, like TIS7, IFN- ⁇ and IFN- ⁇ are induced in neuronal cells within the first hour following explantation.
- IFN- ⁇ expression is modulated at the transcriptional level by multiple regulatory factors that bind upstream of the initiation site, such as the activators IRF-1 and NFkB, and the repressor IRF-2 (reviewed in Tanaka & Taniguchi, 1992).
- the activators IRF-1 and NFkB and the repressor IRF-2 (reviewed in Tanaka & Taniguchi, 1992).
- IRF- 1 was induced by the stress of explantation.
- IRF-2 nor the IFN receptor were induced ( Figure 4). Since the induction of IRF-1 followed the same temporal pattern as that of IFN, IFN- alpha and beta are believed to be induced via an IRF-1 dependent pathway in explanted TG cells (Kawakami et al, 1995).
- IFN induction is a consequence of the stress of explantation, and did not result from viral gene expression, or from incubation in the presence of serum factors.
- IFN is known to possess antiviral properties, and indeed is induced by HSV infection (Gobi et al, 1988a, Green et al, 1981, Stanwick et al, 1982b).
- IFN is an inhibitor of activation of HSV immediate early (IE) genes in vitro by VP16 (LaMarco & Mc Knight, 1989).
- IE immediate early
- Applicants recently found induction of both Early and IE HSV genes during the first hours of viral reactivation (Tal- Singer et al, 1997).
- the absence of viral IE gene expression prior to Early gene expression during the first hours following explantation of TG may be a result of the inhibitory effect of IFN on a neuron-specific VP16 homologue.
- IFN blocks both HSV morphogenesis and release of viral particles from infected cells (Chatterjee et al, 1985). Therefore, an interesting relationship between IFN and reactivating HSV may involve one round of viral replication, allowing the virus to travel from TG neurons to the site of recrudescence in corneal epithelium. Immediate induction of IFN may prevent the spread of reactivating virus within the nervous system by inhibiting release of viral particles and activating host defense mechanisms such as natural killer cells (Habu et al, 1984). Moreover, in another virus system, neuroblastoma cells expressing high levels of IFN-b support persistent rabies virus infections (Honda et al, 1985). This suggests that the IFN response may be involved in ensuring the viability of infected host cells.
- IFN may inhibit viral reactivation in neurons and, in a few cells, other cellular factors override its effects by inducing high levels of viral gene expression.
- Walev et al. Wang et al, 1995
- TNF-a treatment induced the efficiency of reactivation in that study.
- TIS7 The relationship of TIS7, IFN, and viral responses. TIS7 and interferons are induced by viral infection (Skup et al, 1982, Tanaka & Taniguchi, 1992) and, as shown in this study, by the stress of explantation. The precise function of TIS7 in the cell is yet to be elucidated, it is however clear that it plays a role in cellular growth and differentiation (Guardavaccaro et al, 1995, Herschman et al, 1994). Furthermore, it is known that TIS7 has no antiviral activity (Tirone & Shooter, 1989) which is a property of interferons (Tanaka & Taniguchi, 1992).
- PCR differential- display represents an excellent method to screen for species of RNA which are transcriptionally regulated in TG following explantation. Genes identified using this method can be studied in other HSV reactivation systems, resulting in a database of specific genes which may be involved in the reactivation process.
- TIS7 induction was shown in neurons at the protein level, using immunohistochemistry of TG sections.
- IRF- 1 binding in the viral genome Figure 7 (there were significant matches to the IRF-1 consensus binding site). The disclosure of these sites in no way limits the manner in which cellular factors interact with virus sequences during reactivation. Applicants have also demonstrated that IRF- 1 binding sites occur in potentially critical regions of the viral genome, and thus are believed to be crucial in the reactivation process.
- Identified herein are cellular genes induced in response to stimuli that reactivate virus and methods for screening compounds to treat disease based on this observation. Therapies based on this observation are also provided.
- the invention provides that these genes are potential causative agents in reactivation, but this model in no way limit the scope of the invention.
- any polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA.
- the DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand.
- the coding sequence which encodes the polypeptide may be identical to the coding sequence shown or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encoding the same polypeptide.
- the present invention includes variants of the hereinabove described polynucleotides which encode fragments, analogues and derivatives of the polypeptide characterized by the deduced amino acid sequence given herein.
- the variant of the polynucleotide may be a naturally occurring allelic variant of the polynucleotide or a non- naturally occurring variant of the polynucleotide.
- the present invention includes polynucleotides encoding the same polypeptide characterized by the deduced amino acid sequence given herein as well as variants of such polynucleotides which variants encode for a fragment, derivative or analogue of the polypeptide.
- Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.
- the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence characterized by the DNA sequence disclosed herein.
- allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.
- the polynucleotide which encodes for the mature polypeptide may include only the coding sequence for the mature polypeptide or the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence or a proprotein sequence.
- polynucleotide encoding a polypeptide encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.
- the present invention therefore includes polynucleotides, wherein the coding sequence for the mature polypeptide may be fused in the same reading frame to a polynucleotide sequence which aids in expression and secretion of a polypeptide from a host cell, for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell.
- the polypeptide having a leader sequence is a preprotein and may have the leader sequence cleaved by the host cell to form the mature form of the polypeptide.
- the polynucleotides may also encode for a proprotein which is the mature protein plus additional 5' amino acid residues.
- a mature protein having a prosequence is a proprotein and may be an inactive form of the protein.
- the polynucleotide of the present invention may code for a mature protein, or for a protein having a prosequence or for a protein having both a prosequence and a presequence (leader sequence).
- leader sequence the amino acid sequences provided herein show a methionine residue at the NH 2 -terminus. It is appreciated, however, that during post-translational modification of the peptide, this residue may be deleted. Accordingly, this invention contemplates the use of both the methionine-containing and the methionineless amino terminal variants of each protein disclosed herein.
- the polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence at either the 5 ' or 3' terminus of the gene which allows for purification of the polypeptide of the present invention.
- the marker sequence may be a hexa-histidine tag supplied by the pQE series of vectors (supplied commercially by Quiagen Inc.) to provide for purification of the polypeptide fused to the marker in the case of a bacterial host.
- the present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 50% and preferably at least 70% identity between the sequences.
- the present invention particularly relates to Streptococcal polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides .
- stringent conditions means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.
- the polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which retain substantially the same biological function or activity as the polypeptide characterised by the deduced amino acid sequence given herein.
- fragment when referring to the polypeptide characterized by the deduced amino acid sequence herein, means a polypeptide which retains essentially the same biological function or activity as such polypeptide.
- an analogue includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.
- the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.
- the fragment, derivative or analogue of the polypeptide characterized by the deduced amino acid sequence herein may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the polypeptid
- polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.
- isolated means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
- a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated.
- Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
- the present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.
- polypeptide of the invention by recombinant techniques by expressing a polynucleotide encoding said polypeptide in a host and recovering the expressed product.
- polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector.
- the vector may be, for example, in the form of a plasmid, a cosmid, a phage, etc.
- the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes.
- the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- Suitable expression vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA.
- any other vector may be used as long as it is replicable and viable in the host.
- the appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art.
- the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
- promoters there may be mentioned: LTR or SV40 promoter, the E. coli. lac or trp, the phage lambda PL promoter and other promoters known to control expression of genes in eukaryotic or prokaryotic cells or their viruses.
- the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator.
- the vector may also include appropriate sequences for amplifying expression.
- the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
- the gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control" elements), so that the DNA sequence encoding the desired protein is transcribed into RNA in the host cell transformed by a vector containing this expression construction.
- the coding sequence may or may not contain a signal peptide or leader sequence.
- the polypeptides of the present invention can be expressed using, for example, the E. coli tac promoter or the protein A gene (spa) promoter and signal sequence. Leader sequences can be removed by the bacterial host in post-translational processing. See, e.g., U.S. Patent Nos. 4,431,739; 4,425,437; 4,338,397.
- Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
- Two appropriate vectors are PKK232-8 and PCM7.
- Particular named bacterial promoters include lad, lacZ, T3, T7, gpt, lambda PR, PL and trp.
- Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
- regulatory sequences which allow for regulation of the expression of the protein sequences relative to the growth of the host cell.
- Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
- Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.
- An expression vector is constructed so that the particular coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the control sequences being such that the coding sequence is transcribed under the "control" of the control sequences (i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence).
- control i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence.
- Modification of the coding sequences may be desirable to achieve this end. For example, in some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.
- control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector, such as the cloning vectors described above.
- the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site.
- recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly- expressed gene to direct transcription of a downstream structural sequence.
- the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
- the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.
- the vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence may be employed to transform an appropriate host to permit the host to express the protein.
- the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above.
- the constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation.
- the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence.
- a promoter operably linked to the sequence.
- Bacterial pET-3 vectors (Stratagene), pQE70, pQE60, pQE-9 (Qiagen), pbs, pDIO, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNHl ⁇ a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia).
- Eukaryotic pBlueBacIII (Invitrogen), pWLNEO, " pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).
- any other plasmid or vector may be used as long as they are replicable and viable in the host.
- Examples of recombinant DNA vectors for cloning and host cells which they can transform include the bacteriophage 1 (E. coli), pBR322 (E. coli), pACYC177 (E. coli), pKT230 (gram-negative bacteria), pGV1106 (gram-negative bacteria), pLAFRl (gram- negative bacteria), pME290 (non-£. coli gram-negative bacteria), pHV14 (E.
- Polypeptides can be expressed in host cells under the control of appropriate promoters.
- Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
- Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.
- the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.
- Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.
- Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.
- the polypeptide of the present invention may be produced by growing host cells transformed by an expression vector described above under conditions whereby the polypeptide of interest is expressed. The polypeptide is then isolated from the host cells and purified. If the expression system secretes the polypeptide into growth media, the polypeptide can be purified directly from the media. If the polypeptide is not secreted, it is isolated from cell lysates or recovered from the cell membrane fraction. Where the polypeptide is localized to the cell surface, whole cells or isolated membranes can be used as an assayable source of the desired gene product. Polypeptide expressed in bacterial hosts such as E. coli may require isolation from inclusion bodies and refolding.
- polypeptide can be recovered and purified from recombinant cell cultures by methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.
- HPLC high performance liquid chromatography
- polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.
- the polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which have anti-bacterial action. This invention also contemplates the use of the DNA encoding the antigen as a component in a DNA vaccine as discussed more fully below.
- the polypeptides or cells expressing them can be used as an immunogen to produce antibodies thereto.
- These antibodies can be, for example, polyclonal or monoclonal antibodies.
- the term antibodies also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.
- Antibodies generated against the polypeptides of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptides itself. In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.
- Polypeptide derivatives include antigenically or immunologically equivalent derivatives which form a particular aspect of this invention.
- 'antigenically equivalent derivative' encompasses a polypeptide or its equivalent which will be specifically recognised by certain antibodies which, when raised to the protein or polypeptide according to the present invention, interfere with the interaction between pathogen and mammalian host.
- 'immunologically equivalent derivative' as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the interaction between pathogen and mammalian host.
- derivatives which are slightly longer or slightly shorter than the native protein or polypeptide fragment of the present invention may be used.
- polypeptides in which one or more of the amino acid residues are modified may be used.
- Such peptides may, for example, be prepared by substitution, addition, or rearrangement of amino acids or by chemical modification thereof. All such substitutions and modifications are generally well known to those skilled in the art of peptide chemistry.
- the polypeptide such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken.
- the fusion protein may provide stability to the polypeptide.
- the antigen may be associated, for example by conjugation , with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH).
- BSA bovine serum albumin
- KLH keyhole limpet haemocyanin
- a multiple antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.
- any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, Nature. 256:495-497(1975)), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today 4:72(1983)), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
- the hybridomas are screened to select a cell line with high binding affinity and favorable cross reaction with other Streptococcal species using one or more of the original polypeptide and/or the fusion protein.
- the selected cell line is cultured to obtain the desired Mab.
- Hybridoma cell lines secreting the monoclonal antibody are another aspect of this invention.
- phage display technology could be utilised to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v- genes of lymphocytes from humans screened for possessing anti-Fbp or from naive libraries (McCafferty, J. et al, Nature 348:552-554(1990), and Marks, J. et al, Biotechnology 10:779-783(1992)).
- the affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al, Nature 352:624-628(1991)).
- the antibody should be screened again for high affinity to the polypeptide and/or fusion protein.
- a fragment of the final antibody may be prepared.
- the antibody may be either intact antibody of M r approx 150,000 or a derivative of it, for example a Fab fragment or a Fv fragment as described in Skerra, A and Pluckthun, A., Science 240:1038-1040 (1988). If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies.
- the antibody of the invention may be prepared by conventional means for example by established monoclonal antibody technology (Kohler, G. and Milstein, C. (supra. (1975) or using recombinant means e.g. combinatorial libraries, for example as described in Huse, W.D. et al. Science 246:1275-1281 (1989).
- the antibody is prepared by expression of a DNA polymer encoding said antibody in an appropriate expression system such as described above for the expression of polypeptides of the invention.
- the choice of vector for the expression system will be determined in part by the host, which may be a prokaryotic cell, such as E. coli (preferably strain B) or Streptomyces sp. or a eukaryotic cell, such as a mouse C127, mouse myeloma, human HeLa, Chinese hamster ovary, filamentous or unicellular fungi or insect cell.
- the host may also be a transgenic animal or a transgenic plant (for example, as described in Hiatt, A. et al, Nature 340:76-78(1989).
- Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses, derived from, for example, baculoviruses and vaccinia.
- the Fab fragment may also be prepared from its parent monoclonal antibody by enzyme treatment, for example using papain to cleave the Fab portion from the Fc portion.
- the antibody or derivative thereof is modified to make it less immunogenic in the patient.
- the patient is human the antibody may most preferably be Tiumanised'; where the complimentarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody , for example as described in Jones, P. et al, Nature 321:522-525 (1986), or Tempest et al, Biotechnology 9:266-273 (1991).
- the modification need not be restricted to one of fiumanisation' ; other primate sequences (for example Newman, R. et al, Biotechnology 10: 1455-1460 (1992)) may also be used.
- the humanised monoclonal antibody, or its fragment having binding activity form a particular aspect of this invention.
- This invention provides a method of screening drugs to identify those which interfere with the proteins selected as targets herein, which method comprises measuring the interference of the activity of the protein by a test drug. For example if the protein selected has a catalytic activity, after suitable purification and formulation the activity of the enzyme can be followed by its ability to convert its natural substrates. By incorporating different chemically synthesised test compounds or natural products into such an assay of enzymatic activity one is able to detect those additives which compete with the natural substrate or otherwise inhibit enzymatic activity.
- the invention also relates to inhibitors identified thereby.
- a polynucleotide of the invention in genetic immunisation will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al, Hum. Mol. Genet. 1 :363 (1992); Manthorpe et al, Hum. Gene Ther. 4:419 (1963)), delivery of DNA complexed with specific protein carriers ( Wu et al, Biol. Chem. 264: 16985 (1989)), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, Proc. Nat! Acad. Sci. USA.
- a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al, Hum. Mol. Genet. 1 :363 (1992); Manthorpe et al, Hum. Gene Ther. 4:419 (1963)), delivery of DNA complexed with specific protein carriers ( Wu et al, Biol. Chem. 264: 16985
- Suitable promoters for muscle transfection include CMV, RSV, SRa, actin, MCK, alpha globin, adenovirus and dihydrofolate reductase.
- the active agent i.e., the polypeptide, polynucleotide or inhibitor of the invention
- the active agent may be administered to a patient as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.
- the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams.
- Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions.
- suitable conventional carriers for example cream or ointment bases, and ethanol or oleyl alcohol for lotions.
- Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.
- the daily dosage level of the active agent will be from 0.01 to 10 mg/kg, typically around 1 mg/kg.
- the physician in any event will determine the actual dosage which will be most suitable for an individual patient and will vary with the age, weight and response of the particular patient.
- the above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
- a vaccine composition is conveniently in injectable form.
- Conventional adjuvants may be employed to enhance the immune response.
- a suitable unit dose for vaccination is 0.5-5ug/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. Within the indicated dosage range, no adverse toxicologicals effects are expected with the compounds of the invention which would preclude their administration to suitable patients. Screening Assays
- a Factor of the invention may be employed in a screening process for compounds which bind the receptor and which activate (agonists) or inhibit activation of (antagonists) the receptor polypeptide of the present invention.
- polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See Coligan et al, Current Protocols in Immunology l(2):Chapter 5 (1991).
- Factors of the invention are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drugs which stimulate a Factor of the invention on the one hand and which can inhibit the function of a Factor of the invention on the other hand.
- agonists are employed for therapeutic and prophylactic purposes for such conditions as Herpesvirus infections, such as HSV, VZV, HCMV and EBV infections.
- Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as Herpesvirus infection, such as HSV, VZV, HCMV and EBV infections.
- screening procedures involve producing appropriate cells which express the receptor polypeptide of the present invention on the surface thereof. Such cells include cells from mammals, yeast, Drosophila or E.
- Cells expressing the receptor are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response.
- the assays may simply test binding of a candidate compound wherein adherence to the cells bearing the receptor is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the receptor, using detection systems appropriate to the cells bearing the receptor at their surfaces. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.
- cDNA, protein and antibodies to a Factor of the invention may also be used to configure assays for detecting the effect of added compounds on the production of mRNA and protein from a Factor of the invention in cells.
- an ELISA may be constructed for measuring secreted or cell associated levels of protein feom a Factor of the invention using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit or enhance the production of a Factor of the invention (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues. Standard methods for conducting screening assays are well understood in the art.
- Examples of potential antagonists of a Factor of the invention include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligand of a Factor of the invention, e.g., a fragment of the ligand, or small molecules which bind to the receptor but do not elicit a response, so that the activity of the receptor is prevented.
- Prophylactic and Therapeutic Methods include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligand of a Factor of the invention, e.g., a fragment of the ligand, or small molecules which bind to the receptor but do not elicit a response, so that the activity of the receptor is prevented.
- This invention provides methods of treating abnormal conditions related to both an excess of and insufficient amounts of the biological activity of a Factor of the invention. If the activity of a Factor of the invention is in excess, several approaches are available.
- One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit activation by blocking binding of ligands to a Factor of the invention, or by inhibiting a second signal, and thereby alleviating the abnormal condition.
- soluble forms of a Factor of the invention polypeptides still capable of binding the ligand in competition with endogenous Factor of the invention may be administered. Typical embodiments of such competitors comprise fragments of the polypeptide from a Factor of the invention.
- expression of the gene encoding endogenous Factor of the invention can be inhibited using expression blocking techniques.
- Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression. CRC Press, Boca Raton, FL (1988).
- oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee et al, Nucleic Acids Res (1979) 3:173; Cooney et al, Science (1988) 241 :456; Dervan et al, Science (1991) 251 : 1360. These oligomers can be administered per se or the relevant oligomers can be expressed in vivo.
- a therapeutically effective amount of a compound which activates Factor of the invention i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition.
- gene therapy may be employed to effect the endogenous production of a Factor of the invention by the relevant cells in the subject.
- a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above.
- the retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest.
- These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo.
- gene therapy see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Diagnostic Assays
- This invention also relates to the use of a Factor of the invention polynucleotides for use as diagnostic reagents. Detection of a differentially expressed Factor gene associated with a viral infection and/or reactivation, as compared to a normal individual, will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of a Factor gene. Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis.
- RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled Factor gene-derived nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al, Science (1985) 230:1242.
- nuclease protection assays such as RNase and S 1 protection or the chemical cleavage method. See Cotton et al., Proc Natl Acad Sci USA (1985) 85: 4397-4401.
- an array of oligonucleotides probes comprising Factor gene nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations.
- Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability. (See for example: M.Chee et al. Science, Vol 274, pp 610-613 (1996)).
- the diagnostic assays offer a process for diagnosing or determining a susceptibility to
- Herpesvirus infection such as HSV, VZV, HCMV and EBV infection, through detection of mutation or difference in expression in the Factor of gene as compared to normal individuals by the methods described.
- Herpesvirus infection such as HSV, VZV, HCMV and EBV infection
- Assay techniques that can be used to determine levels of a protein, such as an a Factor of the invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples illustrate, but do not limit the invention. EXAMPLES Example 1: Infection of mice and reactivation experiments. 4 to 6 week old female BALB/c BYJ mice were obtained from Jackson
- mice were anesthetized with intraperitoneal injection of ketamine (87mg kg)/xylazine (13 mg/kg), then, after corneal scarification, were inoculated in the eye with 10 4 PFU of HSV-1 17 + (Brown et al, 1973).
- mice were sacrificed by cervical dislocation and TG were isolated. Groups of 6-10 explanted TG were incubated in Dulbecco's Modified Eagle medium supplemented with 5% fetal bovine serum at 37°C for 0, 1, 2, 4 or 24 hours post-explant (p.e.). In a single experiment, TG were explanted in the absence of serum.
- mice were infected following light scarification of both ear pinnae with 10 5 PFU of HSV-1 SC-16 (Harbour et al. 1981).
- transient hyperthermia was induced as described previously (Sawtell et al. 1992). Briefly, mice were placed in a 43°C water bath for 10-12 minutes, then dried and placed in a warm incubator (34°C) for approximately 30 min to prevent hypothermia. At varying times post treatment, mice were sacrificed by cervical dislocation and TG were removed.
- Example 2 Extraction of RNA. Ganglia used for RNA preparation were snap frozen in liquid nitrogen.
- Example 3 Differential Display RT-PCR.
- RNA was prepared from 300 ng RNA from latently- infected TG at 0, 1, 2, and 4 hours p.e. using the Differential Display Kit (TM) (Display Systems Biotech, Inc., Los Angeles, CA), as described by manufacturer. Primers presented in this study are listed in Table 2. Briefly, RNA from each sample was incubated, with one of nine downstream primers containing 1 IT residues and 2 nucleotide anchors (AA, AC, AG, CA, CC, CG, GA, GC, GG), for one hour at 40°C, followed by 5 min at 95°C to inactivate the M-MuLV enzyme. cDNA was stored at -70"C.
- TM Differential Display Kit
- cDNA was subjected to PCR amplification with Display Taq (TM) (Display Systems Biotech) using the original downstream primer, one of 24 10-mer 5' primers, and a- 33 P-dATP (Warthoe, 1995).
- PCR conditions were 35 cycles of 30 sec denaturation at 94"C, 60 sec primer annealing at 40"C, and 60 sec extension at 72"C, employing a Perkin Elmer Cetus Gene Amp PCR System thermocycler. A final extension reaction was then performed for 5 min 72°C .
- Radiolabeled reaction products were subjected to high resolution polyacrylamide/urea gel electrophoresis as described (Liang & Pardee, 1992). Gels were dried on Whatman filters and analyzed by autoradiography. Differentially-displayed PCR bands were cut out from the filter paper and dissolved in DEPC-treated water (Ambion) for 30 min at room temperature followed by 10 min at lOO'C.
- Example 4 Reamplification PCR.
- each differentially displayed band was reamplified in 4 individual PCR reactions.
- T7- T11VVN 3' primers were used, where VV was the original DDRT nucleotide anchor, T7 was a 23 nucleotide portion of the T7 promoter (TAATACGACTC ACTATAGGGCCC), and N was A,G,T, or C.
- the Reamplification reactions included the original upstream primers, 2mM dNTP and the Stoffel fragment of Taq Polymerase (Perkin Elmer Cetus). Reactions were performed under the original DDRT-PCR conditions. PCR products were separated by agarose electrophoresis and the most prominent product among the four parallel reactions was isolated for automated sequencing and further confirmation.
- Isolated reamplification bands were used as templates for synthesis of 32 P labeled ⁇ boprobes with the MAXIsc ⁇ ptTM kit (Ambion , Austin, TX) as described by manufacturer RNase protection assays (RPA) were performed using HybspeedTM RPA kit (Ambion), and 0 5- 1 mg total RNA from a second, new set of latently-infected and uninfected TG explants
- Mouse ⁇ -actm ⁇ boprobes provided with the MAXIsc ⁇ ptTM kit were used as controls
- Probes and protected fragments were analyzed by denaturing polyacrylamide gel electrophoresis (PAGE) and phospho ⁇ maging
- Example 6 PCR amplification of cDNA.
- the second confirmatory PCR using specific primer sets was performed as follows cDNA was generated from 2 mg of total RNA using Superscript Preamphfication kit priming with ohgo (dT) and random hexamers (Gibco BRL) Reactions were performed in 25-ml volumes containing 4% of cDNA, 200 mM each deoxynucleoside t ⁇ phosphate (Pharmacia), 1 mM of each primer , 1 25 U of AmphTaq GoldTM (Perkin Elmer) with PCR Buffer A (Fisher) Primer pairs used are described m Table 3
- Ganglia used for immunohistochemistry were fixed for 24 h with 4% paraformaldehyde in PBS then immersed in 70% ethanol/ 150 mM NaCl for 24 h and embedded in paraffin wax, and 6 mm serial sections were cut and processed as described elsewhere (Randazzo et al, 1995).
- Rabbit polyclonal antisera to HSV-1 (Dako Corporation, Carpinteria, CA) was used for detection of replicating virus as described (Adams et al, 1984, Kesari et al, 1995).
- Rabbit polyclonal anti-mouse interferon-a/b (Lee Biomolecular Research, San Diego, CA), and rabbit polyclonal anti-mouse TNF-a (Genzyme Diagnostics, Cambridge, MA) were used to probe for cytokines.
- Rabbit polyclonal anti-TIS7 was a generous gift from B. Varnum, Amgen, CA. Antigen-expressing cells were detected by an indirect avidin-biotin immunoperoxidase method (Vectastain ABC kit, Vector Labs, Burlingham, CA), with 3,3'-diaminobenzadine (DAB) as the chromagen (Trojanowski et al, 1993).
- RNA was prepared from latently-infected TG at different time points (0, 1, 2, and 4 hours) following explantation into culture media.
- Complementary DNA was amplified using a set of arbitrary PCR primers.
- the PCR products were resolved by PAGE and visualized by autoradiography. Every pair of primers (216 primer combinations) identified a limited number of target sequences within the pool of cDNAs. Thus, a typical reaction generated 50-200 distinct radiolabeled PCR products between 50 and 600 bp in length.
- the majority of PCR products were present at identical levels in samples derived from different time points ( Figure 1). However, over 100 differentially-displayed PCR products were detected and isolated.
- RNA corresponding to the isolated bands was differentially expressed in either uninfected or latently-infected TG explants.
- Reamplified PCR products were used as probes in quantitative RNase protection assays (RPA).
- RNA corresponding to band #56 was induced by 2 hours following explantation of uninfected ( Figure 3 A) and infected (results not shown) explants.
- Phosphorimager quantitation Figure 3B
- Similar results were obtained using probes generated from band #64 (results not shown).
- RNA transcripts corresponding to differentially-displayed bands #56, and #64 were clearly induced in TG by explantation.
- cDNA prepared from a different set of latently infected TG explants was subjected to PCR using primers specific for TIS7 (Table 3. Each PCR reaction yielded single product bands whose expected sizes corresponded to TIS7 cDNA.
- TIS7 detected with these primers was rapidly induced in both infected ( Figure 3C) and uninfected explants (not shown), confirming the RPA results ( Figure 3A).
- TIS7 expression returned to basal levels ( Figure 3C).
- We also confirmed TIS7 induction in neuronal cells by immunostaining using affinity purified polyclonal antisera directed against TIS7 (not shown).
- induction of TIS7 following explantation of ganglia was detected by three independent methods: DDRT- PCR, RPA, and immunostaining.
- HSV latency occurs primarily in neuronal cells which innervate the cornea (Cook et al, 1974, Ramakrishnan et al, 1994, Ramakrishnan et al, 1996). These neurons represent approximately 2% of the neuronal population in the TG (Arvidson, 1977, Marfurt et al, 1989).
- TG sections from latently-infected and uninfected explants were analyzed by immunohistochemistry. IFN ⁇ / ⁇ protein expression was not detected at 0 h p.e., and was induced at 4, 8, and 24 h p.e.
- IFN Interferon Regulatory Factor -1
- IRF Interferon Regulatory Factor -1
- ICSs interferon consensus sequences
- IRF-1 is an activator of IFN-b, whereas IRF-2 functions as a repressor (Watanabe et al, 1991).
- IRF-1 transcription was induced within the first hour p.e., and its profile of induction was strikingly similar to IFN- ⁇ ( Figure 4A).
- IFN ⁇ R or IRF-2 Figure 4 C, 4D.
- IFN ⁇ R IFN- ⁇ receptor
- IRF-2 Figure 4 C, 4D
- TNF-a Soluble tumor necrosis factor (TNF)-a enhances the reactivation frequency and replication of HSV-1 during explant reactivation (Walev et al, 1995).
- RT-PCR was performed using primers specific for TNF- ⁇ . TNF- ⁇ transcripts were induced rapidly following explant ( Figure 6). However, we were unable to detect TNF- ⁇ , a secreted factor, in TG sections by immunostaining.
- Example 15 Oligonucleotides, probes, and electromobility shift assays.
- DNA binding assays were carried out as described previously (Frazier et al., 1996). The reaction was in 20 ul total volume containing 2 ul (20 ug) BSA (NEB) 0.2 ul (2 ug) sheared salmon sperm DNA9 ul buffer D (20 mM herpes, pH7.9, 100 mM KC1, 20% glycerol, 0.2 mM EDTA, 1 mM DTT, protein (usually 1-2 ul) and water. In samples where antibody incunbation was added, the reaction was incubated with unlabeled probe (100 fold) at room T for 20 minutes before the probe ( ⁇ 1 ng, 30K cpm) being added. Reaction was done at RT for 20 minutes.
- Example 16 In vitro translated IRF-1 binds to LAT ISRE.
- IRF-1 protein sample was generated by in vitro transcription and translation of a human IRF-1 DNA template (generous gift from Richard Pine, New York University) by using the rabbit reticulate lysate system (Promega) and incubated with LAT probe. As shown in figure 8, IRF-1 formed a complex LAT ISRE DNA sequence. This complex was supershifted with IRF- 1 specific antisera but not with IRF-2 antisera, indicating the specificity of the interaction. We have been unable to show in gel mobility shift assays competition experiments with oriL site III oligo, and oriS site I oligo possess IRF binding sites (not shown).
- the LAT region ISRE was shown to be able to associate with IRF-2 in phorbol ester stimulated Jurkat cells extracts (Santa Cruz) in gel mobility shift assays (not shown).
- the IRF-2/ISRE complex formed when the LAT probe was incubated with Jurkat cell extracts was competed by wild-type LAT and ISRE probes (Santa Cruz) but not by mutant ISRE mQpinr (Santa Cruz), mutated LAT probes LATmAT and LATmm that contain two and three nucleotide changes, respectively, or and oriS Site I oligo (figure 9).
- Transient hyperthermia is known to cause reactivation of HSV-1 from latency (Sawtell et al, 1992).
- IFN-related genes such as TIS7 and IRF-1 are induced by another reactivation stimulus.
- samples from individual hyperthermia-treated mice were prepared.
- Figure 10A cellular housekeeping genes were realtively similar in all the animals, whereas HSP70, TIS7, and IRF-1 transcription was induced within the first 1-2 hours following hyperthermia ( Figure 10 B, C, D). Similar results were obtained in two experiments using samples obtained from different mice (not shown). Our results suggest that the pathway leading to induction of TIS7 and IRF-1 is common to different reactivation stimuli.
- IRF-1 interferon regulatory factor 1
- IRF-2 interferon regulatory factor 2
- LPS lipopolysaccharide
- Interferon regulatory factor-2 physically interacts with NF-kappa B in vitro and inhibits NF-kappa B induction of major histocompatibility class I and beta 2-microglobulin geneexpression in transfected human neuroblastoma cells.
- IFN regulatory factor- 1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. J. Immunol. 158, 4260-4269. Honda, Y., Kawai, A. & Matsumoto, S. (1985). Persistent infection of rabies virus (HEP- Flury strain) in human neuroblastoma cells capable of producing interferon. J. Gen. Virol. 66, 957-967.
- Nerve injury enhances rat neuronal glutamate transporter expression: identification by differential display PCR. J. Neuroscience 15, 7872-8.
- Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF- 1 promoter tomediate induction by IFN alpha and IFN gamma, and is likely to autoregulate the p91 gene.
- EMBO J 13
- OBF-1 a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins. Cell 80, 497-506.
- TIS7 a gene induced in Swiss 3T3 cells by the tumor promoter tetradecanoyl phorbol acetate. Oncogene 4, 1263-1265.
- IFN-beta element by IRF- 1 requires a posttranslational event in addition to IRF-1 synthesis. Nuc. Ac. Res. 19, 4421-8.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5163397P | 1997-07-03 | 1997-07-03 | |
US51633P | 1997-07-03 | ||
US5451597P | 1997-08-01 | 1997-08-01 | |
US54515P | 1997-08-01 | ||
US8035298P | 1998-04-01 | 1998-04-01 | |
US80352P | 1998-04-01 | ||
PCT/US1998/013733 WO1999001464A1 (en) | 1997-07-03 | 1998-07-01 | Componds and methods for treating and screening viral reactivation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1001967A1 true EP1001967A1 (de) | 2000-05-24 |
EP1001967A4 EP1001967A4 (de) | 2004-12-29 |
Family
ID=27367993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98935519A Withdrawn EP1001967A4 (de) | 1997-07-03 | 1998-07-01 | Behandlungsmethode eines lignocellulosischen materials oder eines expandierten minerals zur formung eines fertigproduktes |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1001967A4 (de) |
JP (1) | JP2002511877A (de) |
CA (1) | CA2295933A1 (de) |
WO (1) | WO1999001464A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005019478A1 (en) * | 2003-08-18 | 2005-03-03 | Irm Llc | Methods and compositions for modulating herpesviral replication and transcription activator |
US8802106B2 (en) | 2009-10-30 | 2014-08-12 | The Administrators Of The Tulane Educational Fund | Peptide compositions and methods for inhibiting herpesvirus infection |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0355190A1 (de) * | 1988-08-24 | 1990-02-28 | Tadatsugu Dr. Taniguchi | Genexpression regulierender Faktor |
-
1998
- 1998-07-01 CA CA002295933A patent/CA2295933A1/en not_active Abandoned
- 1998-07-01 EP EP98935519A patent/EP1001967A4/de not_active Withdrawn
- 1998-07-01 JP JP50735599A patent/JP2002511877A/ja not_active Ceased
- 1998-07-01 WO PCT/US1998/013733 patent/WO1999001464A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO9901464A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1001967A4 (de) | 2004-12-29 |
CA2295933A1 (en) | 1999-01-14 |
WO1999001464A1 (en) | 1999-01-14 |
JP2002511877A (ja) | 2002-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zimmermann et al. | Isolation and characterization of cDNA clones encoding the human carcinoembryonic antigen reveal a highly conserved repeating structure. | |
US8236507B2 (en) | Modulators of TNF receptor associated factor (TRAF), their preparation and use | |
AU697535B2 (en) | Haemopoietic maturation factor | |
US6740738B2 (en) | Antibody against hypoxia proteins | |
EP0567575B1 (de) | Cytokin-induziertes protein, tsg-6, seine dna und verwendung | |
WO1999062952A1 (en) | A human zinc finger protein gene (bmzf2) | |
US20050197307A1 (en) | Compounds and methods for treating and screening viral reactivation | |
WO1999001464A1 (en) | Componds and methods for treating and screening viral reactivation | |
WO1993019179A1 (en) | Ifn receptors recognition factors, protein sequences and methods of use thereof | |
CN112402592A (zh) | Spink7蛋白在制备促进过度炎症创面愈合的药物中的应用 | |
US7524928B2 (en) | IFN receptor 1 binding proteins | |
US6605442B1 (en) | Methods of testing drugs or agents that modulate the activity of receptor recognition factors | |
US7264945B2 (en) | IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons | |
WO1996023410A1 (en) | UBIQUITIN CONJUGATING ENZYMES 7, 8 and 9 | |
CA2264544A1 (en) | Snrnp sm proteins | |
EP1224220A2 (de) | Gen 1 der epo-primärantwort, eprg1 | |
EP0556395B1 (de) | Neuartige cytokine | |
US5945321A (en) | Ubiquitin conjugating enzymes 7, 8 and 9 | |
EP1780277A1 (de) | IFN Rezeptor 1 bindende Proteine, dafür kodierende DNA und Verfahren zur Regulierung der zellulären Antwort auf Interferone | |
MXPA99006595A (en) | Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons | |
AU3508101A (en) | Modulators of TNF receptor associated factor (TRAF), their preparation and use | |
MXPA96003897A (en) | Factor 10 of fibroblas growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991221 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE ES FR GB IT LI NL |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041109 |
|
17Q | First examination report despatched |
Effective date: 20081219 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090501 |